StockIQpro
NASDAQ:CNTX

Context Therapeutics Inc.

Track all markets on TradingView
Track all markets on TradingView

Context Therapeutics Inc. reported net income of −$36.1M in fiscal 2025. Free cash flow was −$26.4M, and the diluted share count rose 62.9%.Summary generated from Context Therapeutics Inc.'s SEC filings. Latest annual report filed Mar 23, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−46.4%
Debt / equityn/a
Free cash flow−$26.4M
FCF marginn/a
Share count change+62.9%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−11−15−25−30−40
Net income−10−15−24−27−36
Free cash flow−9−14−21−15−26

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations